Investigating RUXolitinib for the Treatment of COVID-19 Pneumonia

Technology Overview

RUX-COVID is a single arm open-label clinical study to investigate the efficacy and safety of RUXolitinib. The primary objective of this study is to determine the therapeutic effects of ruxolitinib (an inhibitor of JAK1 and JAK2) on rate and time to clinical recovery in participants with COVID-19 pneumonia.

Stage of Development

The researchers are in the process of finding collaborators across UHN hospitals, MSH, SMH, and Sunnybrook to recruit patients on this study.